Tag: AZD7442

Evusheld significantly prevented COVID-19 disease progression or death in TACKLE Phase III treatment trial

admin

Results published in The Lancet Respiratory Medicine support benefits of Evusheld in the outpatient treatment of mild-to-moderate COVID-19 Detailed results from the TACKLE Phase III outpatient treatment trial showed AstraZeneca’s Evusheld (tixagevimab and cilgavimab, formerly AZD7442) provided clinically and statistically Read More …

AstraZeneca to supply the US government with an additional one million doses of Evusheld long-acting antibody combination for the prevention of COVID-19

admin

Builds on initial US government agreement, now totalling 1.7 million doses  Only antibody therapy authorized in the US for pre-exposure prophylaxis of COVID-19 in people who are immunocompromised AstraZeneca today announced the US Department of Health and Human Services has Read More …

Evusheld (formerly AZD7442) long-acting antibody combination authorised for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19

admin

Only antibody therapy authorised in US for pre-exposure prophylaxis   Pivotal phase III data showed robust efficacy and long-term protection with one dose in high-risk population  AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency Read More …

Liệu pháp bộ đôi kháng thể đơn dòng tác dụng kéo dài AZD7442 (còn có tên là Evusheld) được cấp phép sử dụng khẩn cấp ở Hoa Kỳ cho dự phòng trước phơi nhiễm (phòng ngừa) COVID-19

admin

Liệu pháp kháng thể duy nhất được phê duyệt tại Hoa Kỳ cho dự phòng trước phơi nhiễm  Dữ liệu quan trọng từ thử nghiệm pha III cho thấy thời gian bảo vệ  lâu dài ở nhóm đối tượng có Read More …